Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Epilepsy is one of the most common neurological disorders estimated to affect about 1% of the general population [1]. Until 1992, there were 4 main antiepileptic medications primarily utilized for the treatment of epilepsy and they included phenobarbital, phenytoin, carbamazepine, and valproic acid. After 1992, there was an explosion of medications approved for the treatment of seizures. The most recent agent to be approved by the Food and Drug Administration (FDA) was perampanel marketed under the brand name Fycompa®. Perampanel is approved for use in patients 12 years of age and older for the adjunctive treatment of partial-onset seizures with or without secondary generalized seizures [2]. Perampanel has a novel mechanism of action and is the first agent approved in the AMPA receptor antagonists class of antiepileptic medications [3]. By targeting the AMPA receptor, perampanel decreases neuronal excitatory thereby decreasing seizure activity.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi